AzurRx BioPharma

First Wave Biopharma, Inc. is a clinical stage biopharmaceutical company, which engages in the research and development of non-systemic therapies for the treatment of gastrointestinal diseases. The firm is involved in a therapeutic development pipeline populated with multiple clinical stage programs built around its proprietary technologies, such as Niclosamide, an oral small molecule with anti-viral and anti-inflammatory properties, and the biologic Adrulipase, a recombinant lipase enzyme designed to enable the digestion of fats and other nutrients. Its programs include FW-UP, FW-UC, FW-CD, FW-COV, FW-ICI-AC, MS1819, COVID-19 GI infections, and FW-EPI. The company was founded on January 30, 2014 and is headquartered in Boca Raton, FL.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Entero Therapeutics, Inc. is a clinical stage biopharmaceutical company, which engages in the research and development of non-systemic therapies for the treatment of gastrointestinal diseases. The firm is involved in a therapeutic development pipeline populated with multiple clinical stage programs built around its proprietary technologies, such as Niclosamide, an oral small molecule with anti-viral and anti-inflammatory properties, and the biologic Adrulipase, a recombinant lipase enzyme designed to enable the digestion of fats and other nutrients. Its programs include FW-UP, FW-UC, FW-CD, FW-COV, FW-ICI-AC, MS1819, COVID-19 GI infections, and FW-EPI. The company was founded on January 30, 2014 and is headquartered in Boca Raton, FL.

BOCA RATON, Fla., June 08, 2021 (GLOBE NEWSWIRE) -- AzurRx BioPharma, Inc. (NASDAQ: AZRX), (“AzurRx” or the “Company”), a clinical stage biopharmaceutical company specializing in the development of targeted, non-systemic therapies for gastrointestinal (GI) diseases, announced today that James Sapirstein, Chief Executive Officer of AzurRx, will present at the 2021 BIO Digital. The virtual conference is taking place June 10-11 and June 14-18, 2021.

AzurRx BioPharma CEO James Sapirstein to Present at 2021 BIO Digital

DELRAY BEACH, Fla., May 19, 2021 (GLOBE NEWSWIRE) -- AzurRx BioPharma, Inc. (NASDAQ: AZRX), (“AzurRx” or the “Company”), a clinical stage biopharmaceutical company specializing in the development of targeted, non-systemic therapies for gastrointestinal (GI) diseases, today announced that James Sapirstein, AzurRx President, CEO and Chairman, will present at the Rocky Mountain Microcap Conference on May 26, 2021.

AzurRx BioPharma to Present at Rocky Mountain Microcap Conference (May 26)

AzurRx BioPharma Inc (NASDAQ: AZRX) announced positive interim data from the first 18 out of 20 patients from its Phase 2 trial. The study was evaluating MS1819 in combination with the current standard of care, porcine-derived pancreatic enzyme replacement therapy (PERT), for severe exocrine pancreatic insufficiency (EPI) in patients with cystic fibrosis (CF).

AzurRx BioPharma Stock Gains On Positive MS1819-PERT Combo Data In Pancreatic Insufficiency

Data from first 18 patients indicate MS1819 and PERT combination led to clinically meaningful improvements in primary efficacy endpoint

AzurRx BioPharma Announces Positive Interim Data in Phase 2 Clinical Trial of MS1819 in Combination with PERT in the Treatment of Cystic Fibrosis Patients with Severe Exocrine Pancreatic Insufficiency

DELRAY BEACH, Fla., May 12, 2021 (GLOBE NEWSWIRE) -- AzurRx BioPharma, Inc. (NASDAQ: AZRX), (“AzurRx” or the “Company”), a clinical stage biopharmaceutical company specializing in the development of targeted, non-systemic therapies for gastrointestinal (GI) diseases, today announced that AzurRx SAS, its wholly-owned subsidiary in France, has received approximately 459,000 Euros ($550,000 U.S.) in non-dilutive funding in research tax credits from the French government for its 2020 CIR (French Research Tax Credit).

AzurRx BioPharma Receives Approximately $550K for its 2020 CIR (French Research Tax Credit)

DELRAY BEACH, Fla., May 11, 2021 (GLOBE NEWSWIRE) -- AzurRx BioPharma, Inc. (NASDAQ: AZRX), (“AzurRx” or the “Company”), a clinical stage biopharmaceutical company specializing in the development of targeted, non-systemic therapies for gastrointestinal (GI) diseases, today announced that the Company will make a virtual presentation at the Emerging Growth Conference taking place on Wednesday, May 12th, 2021.

AzurRx BioPharma to Present at the Emerging Growth Conference (May 12)

DELRAY BEACH, Fla., May 11, 2021 (GLOBE NEWSWIRE) -- AzurRx BioPharma, Inc. (NASDAQ: AZRX), (“AzurRx” or the “Company”), a clinical stage biopharmaceutical company specializing in the development of targeted, non-systemic therapies for gastrointestinal (GI) diseases, today announced that James Sapirstein, AzurRx President, CEO and Chairman, will present at Investor Summit Group's Q2 Virtual Investor Summit taking place May 17-18, 2021.

AzurRx BioPharma to Present at Investor Summit Group's Q2 Virtual Investor Summit (May 17)

Delray Beach, Florida--(Newsfile Corp. - May 11, 2021) - AzurRx BioPharma (NASDAQ: AZRX) today announced that James Sapirstein, Chairman, President, and CEO will be attending the Q2 Virtual Investor Summit.  Event Q2 Investor Summit Date May 17-18th, 2021 Presentation May 17th at 09:30 AM ET

AzurRx BioPharma Announces Participation in the Q2 Virtual Investor Summit

BIOLASE

Wrap Technologies

Reopening penny stocks that investors are watching right now The post 3 Reopening Penny Stocks to Watch in April 2021 appeared first on Penny Stocks to Buy, Picks, News and Information | PennyStocks.com.

3 Reopening Penny Stocks to Watch in April 2021

DELRAY BEACH, Fla., April 15, 2021 (GLOBE NEWSWIRE) -- AzurRx BioPharma, Inc. (NASDAQ: AZRX), (“AzurRx” or the “Company”), a clinical stage biopharmaceutical company specializing in the development of targeted, non-systemic therapies for gastrointestinal (GI) diseases, today issued a letter to its shareholders from James Sapirstein, President, Chief Executive Officer and Chairman, highlighting the company's corporate and clinical achievements during the first quarter of 2021 and recent weeks.

AzurRx BioPharma CEO Issues Letter to Shareholders

AzurRx BioPharma Inc (NASDAQ: AZRX) has initiated Phase 2 RESERVOIR trial evaluating oral formulation of micronized niclosamide (FW-1022) for the treatment of COVID-19 related gastrointestinal (GI) infections. Patient enrollment is expected to begin soon, with topline data anticipated in Q1 2022.

AzurRx BioPharma To Test Formulated Niclosamide In COVID-19-Related Gastrointestinal Infections

“RESERVOIR” trial to evaluate niclosamide's ability to target SARS-CoV-2 in the GI tract

AzurRx BioPharma Initiates Phase 2 Clinical Trial of Niclosamide for the Treatment of COVID-19 Gastrointestinal Infections

DELRAY BEACH, Fla., March 31, 2021 (GLOBE NEWSWIRE) -- AzurRx BioPharma, Inc. (NASDAQ: AZRX), (“AzurRx” or the “Company”), a clinical stage biopharmaceutical company specializing in the development of targeted, non-systemic therapies for gastrointestinal (GI) diseases, today provided key takeaways from its conference call reporting on the topline results from its Phase 2b OPTION 2 clinical trial investigating MS1819 in cystic fibrosis (CF) patients with exocrine pancreatic insufficiency (EPI). The conference call, held on March 31, 2021, at 4:30 p.m. ET, featured James Sapirstein, President, CEO and Chairman of AzurRx, and Dr. James Pennington, Chief Medical Officer, discussing the recently completed OPTION 2 study, and the company's plans to develop an optimized formulation of MS1819 for ongoing clinical investigation.

AzurRx BioPharma Provides Key Takeaways from Phase 2b OPTION 2 Clinical Trial Topline Results Conference Call

AzurRx to Host Conference Call and Live Audio Webcast Today, Wednesday, March 31, 2021 at 4:30 p.m. ET AzurRx to Host Conference Call and Live Audio Webcast Today, Wednesday, March 31, 2021 at 4:30 p.m. ET

AzurRx BioPharma to Report Topline Data from Phase 2b OPTION 2 Clinical Trial of MS1819 in Cystic Fibrosis

Top-line data expected in Q2 2021 Top-line data expected in Q2 2021

AzurRx BioPharma Announces Completion of Enrollment in Phase 2 Clinical Trial of MS1819 in Combination with PERT in the Treatment of Cystic Fibrosis Patients with Severe Exocrine Pancreatic Insufficiency

The stock price of AzurRx BioPharma, Inc. (NASDAQ: AZRX) has increased by over 10% pre-market. This is why it happened.

AZRX Stock Price Increases Over 10% Pre-Market: Why It Happened

AzurRx BioPharma Announces Completion of Enrollment in Phase 2b OPTION 2 Clinical Trial of MS1819 in Cystic Fibrosis

The stock price of AzurRx BioPharma Inc (NASDAQ: AZRX) has increased by over 40% pre-market. This is what you should know about the company.

AZRX Stock Price Increaes Over 40% Pre-Market: What You Should Know About The Company

DELRAY BEACH, Fla., March 10, 2021 (GLOBE NEWSWIRE) -- AzurRx BioPharma, Inc. (“AzurRx” or the “Company”) (NASDAQ: AZRX), a company specializing in the development of targeted non-systemic, recombinant therapies for gastrointestinal (GI) diseases, announced today that James Sapirstein, Chairman and Chief Executive Officer, will present during the Maxim Group Emerging Growth Virtual Conference taking place Wednesday, March 17 to Thursday, March 18, 2021. All registered conference attendees will be able to view the prerecorded virtual presentation.

AzurRx BioPharma to Present at the Maxim Group Emerging Growth Virtual Conference (March 17-18)

AzurRx Chairman and CEO, James Sapirstein, to participate in panel discussion on potential developmental therapeutics for SARS-CoV-2 infection AzurRx Chairman and CEO, James Sapirstein, to participate in panel discussion on potential developmental therapeutics for SARS-CoV-2 infection

AzurRx BioPharma to Participate in the 33rd Annual Roth Conference

DELRAY BEACH, Fla., March 02, 2021 (GLOBE NEWSWIRE) -- AzurRx BioPharma, Inc. (“AzurRx” or the “Company”) (NASDAQ: AZRX), a company specializing in the development of targeted non-systemic, recombinant therapies for gastrointestinal (GI) diseases, today announced that James Sapirstein, Chairman and Chief Executive Officer, will participate in a “fireside chat” with Yi Chen, Managing Director, Equity Research at H.C. Wainwright, during the H.C. Wainwright Global Life Sciences Conference being held virtually March 9-11, 2021.

AzurRx BioPharma to Participate in “Fireside Chat” at the H.C. Wainwright Global Life Sciences Conference

Former Chairman Edward J. Borkowski to continue as the lead independent director on the board Former Chairman Edward J. Borkowski to continue as the lead independent director on the board

AzurRx BioPharma Appoints President and CEO James Sapirstein as New Chairman of the Board of Directors

DELRAY BEACH, Fla., Feb. 16, 2021 (GLOBE NEWSWIRE) -- AzurRx BioPharma, Inc. (“AzurRx” or the “Company”) (NASDAQ: AZRX), a company specializing in the development of targeted non-systemic, recombinant therapies for gastrointestinal (GI) diseases, today announced that James Sapirstein, Chief Executive Officer, will present at The Microcap Rodeo Winter Wonderland Conference taking place virtually from February 16-19, 2021.

AzurRx BioPharma to Present at The Microcap Rodeo Winter Wonderland Conference

USANA Health Sciences

AbCellera Biologics

Cancer Genetics

Usana Health Sciences (NYSE: USNA) shares are trading higher after the company reported better-than-expected Q4 EPS and sales results and issued fiscal year 2021 EPS and sales guidance above estimates. The company also announced a $150 million buyback.

Why AzurRx BioPharma, Usana Health Are Moving Today

Phase 2 Study of oral niclosamide planned for 1H 2021

News for AzurRx BioPharma Stock (AZRX)